CRC imaging technique identifies early extracolonic lesions of colorectal cancer

NewsGuard 100/100 Score

Although the medical community has already accepted that colorectal cancer (CRC) screening is cost effective and saves lives, researchers have found that computed tomography colonography (CTC or virtual colonoscopy) not only identifies CRC but also doubles the yield of identifying significant early extracolonic (outside the colon) lesions, resulting in lives saved, according to a study in the September issue of the American Journal of Roentgenology (www.ajronline.org).

CTC is an emerging noninvasive rapid imaging technique developed for colorectal cancer (CRC) screening. It is less invasive than optical colonoscopy and may improve patient adherence and CRC screening.

In addition to intracolonic (within the colon) findings, CTC examines the entire abdomen and pelvis similarly to a CT scan. "The ability of CTC to identify significant extracolonic lesions at an early treatable stage may increase the yield of CRC screening, thus enhancing CTC as a major screening technique," said Ganesh R. Veerappan, MD, lead author of the study.

The study, performed at Walter Reed Army Medical Center in Washington, DC, included 2,277 patients who underwent CTC. Of those patients, extracolonic findings were identified in 1,037 patients, with 787 insignificant and 240 significant findings.

"When considering extracolonic findings, CTC increased the odds of identifying high-risk lesions by 78 percent. CTC should be considered as an alternative to optimal colonoscopy for colorectal cancer screening or as a onetime procedure to identify significant treatable intracolonic and extracolonic lesions," said Veerappan.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy